Primary central nervous system tumors survival in children in ten Colombian cities: a VIGICANCER report
- PMID: 38505512
- PMCID: PMC10949889
- DOI: 10.3389/fonc.2023.1326788
Primary central nervous system tumors survival in children in ten Colombian cities: a VIGICANCER report
Abstract
Purpose: Primary central nervous system (CNS) tumors are the second most common cancer in children and adolescents, leading to premature death and disability. Population-based survival estimates aid decision-making in cancer control, however data on survival for primary CNS tumors in Latin America is lacking. We describe survival rates for children with primary CNS tumors treated in ten Colombian cities.
Methods: We analyzed data from children and adolescents newly diagnosed with cancer between 2012 and 2021, participating in the Childhood Cancer Clinical Outcomes Surveillance System (VIGICANCER) in ten cities in Colombia. VIGICANCER collects information on clinical outcomes from twenty-seven pediatric oncology units and conducts active follow-up every three months. VIGICANCER does not register craniopharyngiomas; we excluded intracranial germ cell tumors for this report. We used the Kaplan-Meier method to estimate the overall survival probability, stratified by sociodemographic variables, topography, WHO grading, receipt of radiation therapy, and type of surgical resection. We analyzed the prognostic capacity of variables using multivariate proportional Cox's regression, stratified by city and year of diagnosis.
Results: During the study period, VIGICANCER included 989 primary CNS tumors in 879 children and 110 adolescents. The cohort median age was 9 years; 53% of patients were males, and 8% were Afro-descendants. Most common tumors were supratentorial astrocytomas (47%), astrocytic tumors (35%), medulloblastomas (20%), ependymomas (11%), and mixed and unspecified gliomas (10%). Five-year overall survival of the entire cohort was 54% (95% CI, 51-58); for supratentorial gliomas, WHO grade I was 77%, II was 62%, III-IV was 27%, respectively, and for medulloblastoma was 61%. The adjusted hazard rate ratio for patients with WHO grade III and IV, for those with subtotal resection, for brainstem location, and for those not receiving radiation therapy was 7.4 (95% CI, 4.7-11.8), 6.4 (95% CI, 4.2-9.8), 2.8 (95% 2.1-3.8), 2.0 (95% CI, 1.3-2.8) and 2.3 (95% CI, 1.7-3.0), respectively.
Conclusion: We found that half of Colombia's children and adolescents with primary CNS tumors survive five years, compared to 70% to 80% in high-income countries. In addition to tumor biology and location, gross total resection was crucial for improved survival in this cohort. Systematic monitoring of survival and its determinants provides empirical data for guiding cancer control policies.
Keywords: Latin America; central nervous system neoplasms; children; epidemiology; pediatrics; prognosis; survival; treatment outcome.
Copyright © 2024 Ramirez, Piedrahita, Ardila, Pardo, Cabrera-Bernal, Lopera, Suarez, Portilla, Narváez, Rodriguez, Castro, Castro, Estupinan-Perico, Valencia, Álvarez, Fox, Bravo and Aristizabal.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




Similar articles
-
Increased Early-Mortality in Children With Solid Tumors During the COVID-19 Pandemic in a Middle-Income Country.Cancer Med. 2024 Dec;13(24):e70483. doi: 10.1002/cam4.70483. Cancer Med. 2024. PMID: 39711262 Free PMC article.
-
Implementing a Childhood Cancer Outcomes Surveillance System Within a Population-Based Cancer Registry.J Glob Oncol. 2018 Sep;4:1-11. doi: 10.1200/JGO.17.00193. J Glob Oncol. 2018. PMID: 30241253 Free PMC article.
-
Improved survival in the largest national cohort of adults with cerebellar versus supratentorial low-grade astrocytomas.Neurosurg Focus. 2013 Feb;34(2):E7. doi: 10.3171/2012.12.FOCUS12343. Neurosurg Focus. 2013. PMID: 23373452
-
Treatments for astrocytic tumors in children: current and emerging strategies.Paediatr Drugs. 2006;8(3):167-78. doi: 10.2165/00148581-200608030-00003. Paediatr Drugs. 2006. PMID: 16774296 Review.
-
Central nervous system.Cancer Biomark. 2010;9(1-6):193-210. doi: 10.3233/CBM-2011-0177. Cancer Biomark. 2010. PMID: 22112477 Review.
Cited by
-
Epidemiology and Outcome of Primary Central Nervous System Tumors Treated at King Hussein Cancer Center.Cancers (Basel). 2025 Feb 9;17(4):590. doi: 10.3390/cancers17040590. Cancers (Basel). 2025. PMID: 40002185 Free PMC article.
-
Postoperative complications after central nervous system tumor resection in pediatric patients admitted to an intensive care unit in Colombia.Front Oncol. 2024 Dec 6;14:1491943. doi: 10.3389/fonc.2024.1491943. eCollection 2024. Front Oncol. 2024. PMID: 39711949 Free PMC article.
-
Increased Early-Mortality in Children With Solid Tumors During the COVID-19 Pandemic in a Middle-Income Country.Cancer Med. 2024 Dec;13(24):e70483. doi: 10.1002/cam4.70483. Cancer Med. 2024. PMID: 39711262 Free PMC article.
-
Addressing population-level cancer data needs in northwestern Mexico: results from a South-South Colombian-Mexican partnership.Rev Panam Salud Publica. 2025 May 27;49:e53. doi: 10.26633/RPSP.2025.53. eCollection 2025. Rev Panam Salud Publica. 2025. PMID: 40433194 Free PMC article.
References
-
- Steliarova-Foucher E, Colombet M RL, Hesseling P, Moreno F, Shin HY, tiller CA. International Incidence of Childhood Cancer, Volume III (electronic version). Lyon, France: International Agency for Research on Cancer; (2017). Available at: http://iicc.iarc.fr/results/.
LinkOut - more resources
Full Text Sources